title: Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects.
abstract: Several side-effects of asparaginase therapy have been said to be a consequence of the glutaminase activity of Escherichia coli asparaginase, especially the deleterious influence on the liver function. We report here the drug-induced impairments of asparagine and glutamine metabolism in correlation to concentrations changes of plasma proteins, synthesized in the liver, in patients with acute lymphatic leukaemia. One hour after asparaginase application, plasma glutamine decreased to 5% (0-39%: median, range) of the initial values, with a subsequent rise to concentrations slightly lower than those prior to therapy. During the 14 days of drug application the fasting plasma concentrations of glutamine fell to a median of 63% of the pre-therapeutic levels, indicating a depletion of the glutamine pools. Two days after the end of asparaginase application, in one patient the glutamine concentrations increased to the pre-therapeutic range. Plasma concentrations of fibrinogen and antithrombin III decreased to 46% and 56%, respectively, of the initial values, with a slight increase 2 days after the end of therapy. The changes of plasma protein concentrations followed the course of plasma glutamine and asparagine. From that we deduce that the hepatic synthesis of the plasma proteins might be influenced by asparagine and glutamine depletion as a consequence of the therapy with E. coli asparaginase.
authors.affiliation: Department of Internal Medicine II, University of Cologne, FRG.
authors.forename: G
authors.initials: G
authors.lastname: Ollenschläger
authors.forename: E
authors.initials: E
authors.lastname: Roth
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.forename: S
authors.initials: S
authors.lastname: Jansen
authors.forename: A
authors.initials: A
authors.lastname: Simmel
authors.forename: B
authors.initials: B
authors.lastname: Mödder
mesh_terms: D000596:Amino Acids / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D005260:Female; D005973:Glutamine / Q000378:metabolism*; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy
chemical_list: D000596:Amino Acids; D005973:Glutamine; D001215:Asparaginase